Middle East’s pioneering Cardiovascular Symposium returns to underscore the role of biomarker testing in heart failure management
- The second edition of iCaRE highlights the importance of cardiac biomarkers in providing optimal patient care
- Prof. Abdullah Shehab, President of the Emirates Cardiac Society, lends his support to the conference
Dubai, UAE, 25th November 2018: The Middle East’s foremost Cardiovascular Regional Experts Symposia – iCaRE, which debuted in 2017, is back for a second year with an even bigger gathering of the region’s cardiovascular experts, to discuss the latest advances and best practices in biomarker testing and cardiac disease management.
Two -thirds of all deaths in the UAE are caused by cardiovascular disease, making it the leading cause of death in the country[i], which makes reversing its growing rate one of the government’s top priorities as part of its Vision 2021.
Aligning with this vision, the second edition of iCaRE witnessed doctors, cardiology specialists, lab physicians and emergency department doctors, from across the region gather on Saturday, 24 November in Dubai to discuss the latest updates in cardiovascular disease management. Part of the discussion was also heart failure management, and the latest approach to biomarkers testing based on clinical guidelines and laboratory consensus, for management of heart attacks and atrial fibrillation.
Powered by Roche Diagnostics Middle East FZCO (RDME)– the leading IVD partner of choice in the Middle East, this year’s iCaRE was attended by key regional experts like Professor Abdullah Shehab, Professor of Medicine Department of Internal Medicine Faculty of medicine and Health Sciences - United Arab Emirates University, and also the Consultant Interventional Cardiologist (Al Ain and Mediclinic Hospitals), who also chaired the program.
“The UAE ‘s priority is the health and wellbeing of its citizens; therefore, we are happy to support initiatives such as iCaRE which are dedicated to finding solutions to health concerns like cardiovascular disease that are high on our radar given its rampant occurrence. We want our people to receive the highest quality of care and support to live their best lives. Gatherings such as iCaRE help expedite the process by actively sharing knowledge, key learnings and ideas amongst the best healthcare and laboratory experts in the region” said Professor Abdullah Shehab.
Harald Wolf, General Manager of Roche Diagnostics Middle East said, “It has been encouraging to witness the elevated response and attendance to this year’s iCaRE, which only goes to show how necessary and valued such platforms are, given the alarming impact of cardiovascular disease in the country and across the region. Our dedication towards finding solutions to significantly reduce its occurrence is further strengthened each year, as we are determined to help the UAE government work towards its vision of a healthier nation. We put patient-care at the heart of our endeavours, and we are grateful to our partners across the region and to Professor Abdullah Shehab for their continuous support in helping us try and affect such positive changes”.
[i] Life expectancy and main causes of mortality in UAE: A systematic analysis from the Global Burden of Disease Study 1990 — 2016’.